Skip to main content

Table 2 Univariate and multivariate analyses for overall survival in CRC

From: Identification of an at-risk subpopulation with high immune infiltration based on the peroxisome pathway and TIM3 in colorectal cancer

 

Univariate analysis

Multivariate analysis

 

HR (95% CI)

p

HR (95% CI)

p

Gender

 Female

1

   

 Male

1.23 (0.98–1.50)

0.076

  

Stage

 I

1

 

1

 

 II

1.70 (0.94–3.10)

0.082

1.45 (0.79–2.66)

0.225

 III

2.34 (1.28–4.25)

0.006

1.74 (0.95–3.21)

0.074

 IV

8.26 (4.50–15.18)

< 0.001

6.07 (3.25–11.35)

< 0.001

Location

 Left colon, rectum

1

   

 Right colon

1.13 (0.90–1.42)

0.304

  

Microsatellite

 MSI

1

   

 MSS

1.11 (0.78–1.58)

0.566

  

CMS

 CMS1

1

 

1

 

 CMS2

0.97 (0.67–1.38)

0.848

0.94 (0.63–1.39)

0.743

 CMS3

0.70 (0.42–1.16)

0.171

0.67 (0.37–1.17)

0.160

 CMS4

1.45 (1.00–2.11)

0.049

1.10 (0.74–1.64)

0.625

 Indeterminate

1.55 (0.98–2.46)

0.064

1.41 (0.87–2.29)

0.159

KRAS status

 Wild-type

1

 

1

 

 Mutated

1.27 (1.01–1.61)

0.043

1.29 (1.00–1.66)

0.048

BRAF status

 Wild-type

1

   

 Mutated

1.23 (0.85–1.79)

0.28

  

TP53 status

Wild-type

1

   

Mutated

1.20 (0.92–1.57)

   

CIMP

 Low

1

   

 High

1.14 (0.83–1.57)

   

Group

 Group I + II

1

 

1

 

 Group III

1.68 (1.30–2.17)

< 0.001

1.41 (1.05–1.90)

0.023

 Group IV

1.20 (0.90–1.60)

0.223

1.06 (0.77–1.48)

0.709

  1. GSE39582 and TCGA samples of CRC were pooled for this analysis
  2. Abbreviations: HR hazard ratio